Abstract:The transgenic adenocarcinoma of the mouse prostate (TRAMP) model is based on probasin promoter-driven expression of SV40 T-antigen (Tag) to inactivate p53 and Rb tumor suppressor to propel proliferative lesions and aggressive cancers in the prostate. The genetic background of mice (FVB vs. C57BL/6) has been known to profoundly affect the pathogenesis profiles and disease severity. A recent study suggested prostate lobe specificity of neuro-endocrine (NE) carcinomas vs. glandular epithelial lesions, challenging the classical notion of single-lineage disease progression from early epithelial lesions to poorly differentiated carcinomas. Because of the increasing use of this model for chemoprevention studies, it is critical to further characterize the lobe-specificity of lesion lineages in the prostate and determine their responses to chemopreventive agents. To this end, we carefully dissected the dorsolateral (DLP) and ventral prostate (VP) and macroscopic tumors from 30 male C57BL/6 TRAMP mice at 24-weeks of age and fixed tissues in 10% formalin for pathology diagnosis. Our results show that macroscopic tumors were Tag + , synaptophysin (Syp) + , androgen-receptor (AR) − and E-cadherin − NE carcinomas (poorly differentiated carcinomas) and were dissected exclusively from VP, not DLP. Lesions identified in lymph node, liver or lung of such NE-carcinoma bearing mice showed concordant patterns of biomarkers with the primary prostate NE-carcinomas and represent their metastases. In the DLP, we found lesions ranging from mild (formerly as low grade PIN), moderate to atypical hyperplasia of Tag (formerly as moderately differentiated adenocarcinoma) with Tag + , AR + and E-cadherin + expression and no NE-carcinoma. For assessing the impact of selenium on the long term survival from different lineages of prostate lesions, we analyzed archival tissues from a survival study published recently (Wang et al, Cancer Prev Res 2009): TRAMP mice received a daily oral dose of 3 mg Se/kg body weight as methylseleninic acid (MSeA) beginning at 10 weeks (n=31) or 16 weeks of age (n=30), or water (n=31) until euthanasia or 50 weeks of age. MSeA supplementation significantly delayed death from NE-carcinomas (30% life-time incidence). MSeA also prolonged survival of mice with enlarged seminal vesicle containing epithelial-stromal tumors that were Tag + , Syp − , E-cadherin + and AR +/low in the older TRAMP mice (>30 weeks). Interestingly, mice with enlarged seminal vesicle often had normal sized prostate. In summary, the C57BL/6 TRAMP mouse model represents two lineages of prostate carcinogenesis with an involvement of seminal vesicle tumorigenesis in older mice. Future chemoprevention studies should incorporate this new knowledge for efficacy assessment and for molecular target validations. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 949.

Dissociation of Epithelial and Neuroendocrine Carcinoma Lineages in the Transgenic Adenocarcinoma of Mouse Prostate Model of Prostate Cancer.

Abstract 949: Different Lineages of Carcinogenesis in Prostate Lobes in the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) Model in C57BL/6 Background and Their Responses to Chemopreventive Selenium

Lobe-specific Lineages of Carcinogenesis in the Transgenic Adenocarcinoma of Mouse Prostate and Their Responses to Chemopreventive Selenium.

Lobe-Specific Carcinogenesis in the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) Mouse Model

Abstract 5565: Differential Changes of Proteome Profiles in the Dorsal-Lateral Vs. Ventral Prostate of During TRAMP Carcinogenesis

Transcriptomic analysis of mouse TRAMP cell lines and tumors provide insights into shared pathways and therapeutic targets

Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism

Anti-androgen Therapy Induces Transcriptomic Reprogramming in Metastatic Castration-Resistant Prostate Cancer in a Murine Model.

Lobe-specific Proteome Changes in the Dorsal-Lateral and Ventral Prostate of TRAMP Mice Versus Wild-Type Mice

An orthotopic prostate cancer model for new treatment development using syngeneic or patient‐derived tumors

Quantitative proteomics of TRAMP mice combined with bioinformatics analysis reveals that PDGF-B regulatory network plays a key role in prostate cancer progression.

LONGITUDINAL COHORT ANALYSIS OF LETHAL PROSTATE CANCER PROGRESSION IN TRANSGENIC MICE

Adoptive Transfer of Myeloid-Derived Suppressor Cells and T Cells in a Prostate Cancer Model

A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon

Temporally Controlled Ablation of PTEN in Adult Mouse Prostate Epithelium Generates a Model of Invasive Prostatic Adenocarcinoma

Cdna Microarray Analysis of Transgenic and Knock-in Prostate Cancer Mouse Models

Deletion of tumor suppressors adenomatous polyposis coli and Smad4 in murine luminal epithelial cells causes invasive prostate cancer and loss of androgen receptor expression

Early and Delayed Castrations Confer a Similar Survival Advantage in TRAMP Mice

Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors.

Loss of epithelial AR increase castration resistant stem-like prostate cancer cells and promotes cancer metastasis via TGF-β1/EMT pathway

Androgen signaling is a confounding factor for β-catenin-mediated prostate tumorigenesis